7 July 2022 – The European Medicines Agency (EMA) started a rolling review for a version of Spikevax adapted to provide better protection against SARS-CoV-2 variants. The review concerns a bivalent vaccine. This means it will target two strains of SARS-CoV-2, in this case the original strain and the Omicron variant of concern.

For more information, see here.